Liquidia Corporation (NASDAQ: LQDA) shares plummeted 5.05% in Monday's pre-market trading, despite reporting better-than-expected third-quarter results. The biopharmaceutical company, focused on developing treatments for pulmonary and vascular diseases, delivered a surprisingly strong financial performance that surpassed analysts' expectations.

For the third quarter ended September 30, 2025, Liquidia reported a net loss of $0.04 per share, significantly narrower than the $0.40 loss per share anticipated by analysts. This marks a substantial improvement from the $0.40 loss per share recorded in the same period last year. The company's revenue surged to $54.3 million, dramatically exceeding the consensus estimate of $18.8 million and representing a massive increase from $4.4 million in the prior-year quarter.

The impressive financial results were primarily driven by the strong performance of YUTREPIA, Liquidia's inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company recorded $51.7 million in net product sales of YUTREPIA, achieving profitability in the first full quarter since its launch. Despite these positive developments, the stock's unexpected decline suggests that investors may be engaging in profit-taking or harboring concerns about the sustainability of this growth trajectory. The market's reaction underscores the complexity of factors influencing stock prices, even in the face of seemingly positive financial results.